Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Status:
Completed

Trial end date:
2019-02-04

Target enrollment:

Participant gender:

To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.

Phase 2

Amgen